Aloke V Finn

List of Publications by Year
in descending order

156 papers	21,064 citations	34105 52 h-index	9589 142 g-index
161 all docs	161 docs citations	161 times ranked	16017 citing authors

#	Article	IF	Citations
1	Pathology of Drug-Eluting Stents in Humans. Journal of the American College of Cardiology, 2006, 48, 193-202.	2.8	2,537
2	Intraplaque Hemorrhage and Progression of Coronary Atheroma. New England Journal of Medicine, 2003, 349, 2316-2325.	27.0	1,319
3	Pathological Correlates of Late Drug-Eluting Stent Thrombosis. Circulation, 2007, 115, 2435-2441.	1.6	1,200
4	Atherosclerotic Plaque Progression and Vulnerability to Rupture. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2054-2061.	2.4	1,197
5	Concept of Vulnerable/Unstable Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1282-1292.	2.4	982
6	Update on acute coronary syndromes: the pathologists' view. European Heart Journal, 2013, 34, 719-728.	2.2	849
7	The Pathology of Neoatherosclerosis in Human Coronary Implants. Journal of the American College of Cardiology, 2011, 57, 1314-1322.	2.8	834
8	Vascular Responses to Drug Eluting Stents. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1500-1510.	2.4	826
9	Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients. Circulation, 2008, 118, 1138-1145.	1.6	818
10	Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents. Journal of the American College of Cardiology, 2008, 52, 333-342.	2.8	594
11	The thin-cap fibroatheroma: a type of vulnerable plaque: The major precursor lesion to acute coronary syndromes. Current Opinion in Cardiology, 2001, 16, 285-292.	1.8	584
12	Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents. Circulation, 2005, 112, 270-278.	1.6	560
13	Histopathologic Characteristics of Atherosclerotic Coronary Disease and Implications of the Findings for the Invasive and Noninvasive Detection of Vulnerable Plaques. Journal of the American College of Cardiology, 2013, 61, 1041-1051.	2.8	438
14	Pathology of Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus- and Paclitaxel-Eluting Stents in Humans. Circulation, 2014, 129, 211-223.	1.6	422
15	Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nature Reviews Cardiology, 2016, 13, 79-98.	13.7	399
16	Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 191-204.	2.4	352
17	Frequency and Distribution of Thin-Cap Fibroatheroma and Ruptured Plaques in Human Coronary Arteries. Journal of the American College of Cardiology, 2007, 50, 940-949.	2.8	326
18	The importance of the endothelium in atherothrombosis and coronary stenting. Nature Reviews Cardiology, 2012, 9, 439-453.	13.7	314

#	Article	IF	Citations
19	Coronary Responses and Differential Mechanisms of Late Stent Thrombosis Attributed to First-Generation Sirolimus- and Paclitaxel-Eluting Stents. Journal of the American College of Cardiology, 2011, 57, 390-398.	2.8	283
20	Coronary Artery Calcification andÂitsÂProgression. JACC: Cardiovascular Imaging, 2018, 11, 127-142.	5.3	282
21	Hemoglobin Directs Macrophage Differentiation and Prevents Foam Cell Formation in Human Atherosclerotic Plaques. Journal of the American College of Cardiology, 2012, 59, 166-177.	2.8	265
22	Incidence and Predictors of Drug-Eluting Stent Fracture in Human Coronary Artery. Journal of the American College of Cardiology, 2009, 54, 1924-1931.	2.8	229
23	Pathological Findings at Bifurcation Lesions. Journal of the American College of Cardiology, 2010, 55, 1679-1687.	2.8	228
24	CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis. Journal of Clinical Investigation, 2018, 128, 1106-1124.	8.2	209
25	Microthrombi as a Major Cause of Cardiac Injury in COVID-19. Circulation, 2021, 143, 1031-1042.	1.6	196
26	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ, The, 2013, 347, f6530-f6530.	6.0	194
27	Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis. Journal of the American College of Cardiology, 2021, 77, 314-325.	2.8	177
28	2-deoxy-2-[18F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis. Nature Medicine, 2014, 20, 215-219.	30.7	159
29	Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries: AÂpathology study. Atherosclerosis, 2015, 241, 772-782.	0.8	151
30	Drug-eluting coronary stents: insights from preclinical and pathology studies. Nature Reviews Cardiology, 2020, 17, 37-51.	13.7	150
31	Fully bioresorbable vascular scaffolds: lessons learned and future directions. Nature Reviews Cardiology, 2019, 16, 286-304.	13.7	143
32	Coronary Computed Tomography Angiography From Clinical Uses to Emerging Technologies. Journal of the American College of Cardiology, 2020, 76, 1226-1243.	2.8	140
33	Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. Circulation, 2021, 143, 479-500.	1.6	132
34	Pharmacological Suppression of Hepcidin Increases Macrophage Cholesterol Efflux and Reduces Foam Cell Formation and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 299-307.	2.4	129
35	Comparison of pathology of chronic total occlusion with and without coronary artery bypass graft. European Heart Journal, 2014, 35, 1683-1693.	2.2	119
36	Diversity of macrophage phenotypes and responses in atherosclerosis. Cellular and Molecular Life Sciences, 2020, 77, 1919-1932.	5.4	118

#	Article	IF	Citations
37	Ex Vivo Assessment of Vascular Response to Coronary Stents by Optical Frequency Domain Imaging. JACC: Cardiovascular Imaging, 2012, 5, 71-82.	5.3	113
38	Optical coherence tomography in coronary atherosclerosis assessment and intervention. Nature Reviews Cardiology, 2022, 19, 684-703.	13.7	106
39	Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 491-502.	3.3	104
40	Causes of Early Stent Thrombosis in Patients Presenting With Acute Coronary Syndrome. Journal of the American College of Cardiology, 2014, 63, 2510-2520.	2.8	102
41	Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. European Heart Journal, 2013, 34, 3304-3313.	2.2	100
42	New insights into the role of iron in inflammation and atherosclerosis. EBioMedicine, 2019, 47, 598-606.	6.1	96
43	Calcium deposition within coronary atherosclerotic lesion: Implications for plaque stability. Atherosclerosis, 2020, 306, 85-95.	0.8	94
44	Calcified Plaques in Patients WithÂAcuteÂCoronary Syndromes. JACC: Cardiovascular Interventions, 2019, 12, 531-540.	2.9	92
45	Early clinical and angiographic outcomes after robotic-assisted coronary artery bypass surgery. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 179-185.	0.8	83
46	CD163 interacts with TWEAK to regulate tissue regeneration after ischaemic injury. Nature Communications, 2015, 6, 7792.	12.8	75
47	Drug-eluting stent safety: findings from preclinical studies. Expert Review of Cardiovascular Therapy, 2008, 6, 1379-1391.	1.5	72
48	Microthrombi and ST-Segmentâ€“Elevation Myocardial Infarction in COVID-19. Circulation, 2020, 142, 804-809.	1.6	68
49	Understanding the Impact of Stent and Scaffold Material and Strut Design on Coronary Artery Thrombosis from the Basic and Clinical Points of View. Bioengineering, 2018, 5, 71.	3.5	66
50	Eruptive Calcified Nodules as a Potential Mechanism of Acute Coronary Thrombosis and Sudden Death. Journal of the American College of Cardiology, 2021, 77, 1599-1611.	2.8	64
51	Genetic Regulation of Atherosclerosis-Relevant Phenotypes in Human Vascular Smooth Muscle Cells. Circulation Research, 2020, 127, 1552-1565.	4.5	60
52	Pathology of Drug-Eluting Versus Bare-Metal Stents in Saphenous Vein Bypass Graft Lesions. JACC: Cardiovascular Interventions, 2012, 5, 666-674.	2.9	54
53	The role of iron metabolism as a mediator of macrophage inflammation and lipid handling in atherosclerosis. Frontiers in Pharmacology, 2014, 5, 195.	3.5	54
54	Sirolimus-FKBP12.6 Impairs Endothelial Barrier Function Through Protein Kinase C-Î± Activation and Disruption of the p120â€“Vascular Endothelial Cadherin Interaction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2425-2431.	2.4	53

#	Article	IF	Citations
55	Histopathologic Characterization of Peripheral Arteries in Subjects With Abundant Risk Factors. JACC: Cardiovascular Imaging, 2019, 12, 1501-1513.	5.3	53
56	Clinical and Angiographic Results After Hybrid Coronary Revascularization. Annals of Thoracic Surgery, 2014, 97, 484-490.	1.3	51
57	Histopathological Differential Diagnosis ofÂOptical Coherence Tomographic ImageÂInterpretation After Stenting. JACC: Cardiovascular Interventions, 2016, 9, 2511-2523.	2.9	50
58	Differential Healing Responses in Polymer- and Nonpolymer-Based Sirolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2008, 1, 535-544.	2.9	48
59	Do vulnerable and ruptured plaques hide in heavily calcified arteries?. Atherosclerosis, 2013, 229, 34-37.	0.8	47
60	Drug-eluting stents for diabetes mellitus. Journal of the American College of Cardiology, 2005, 45, 479-483.	2.8	45
61	Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. Pharmacological Research, 2015, 93, 22-27.	7.1	45
62	Smooth muscle cellâ€“specific fibronectin-EDA mediates phenotypic switching and neointimal hyperplasia. Journal of Clinical Investigation, 2019, 130, 295-314.	8.2	45
63	Calcified Nodule. JACC: Cardiovascular Interventions, 2016, 9, e125-e126.	2.9	44
64	Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing. European Heart Journal, 2020, 41, 786-796.	2.2	41
65	Linking Hemorrhage, Angiogenesis, Macrophages, and Iron Metabolism in Atherosclerotic Vascular Diseases. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, e33-e39.	2.4	38
66	Comparison of Biologic Effect and Particulate Embolization after Femoral Artery Treatment with Three Drug-Coated Balloons in Healthy Swine Model. Journal of Vascular and Interventional Radiology, 2019, 30, 103-109.	0.5	38
67	Metformin Impairs Vascular Endothelial Recovery After Stent Placement in the Setting of Locally Eluted Mammalian Target of Rapamycin Inhibitors Via S6 Kinase-Dependent Inhibition of Cell Proliferation. Journal of the American College of Cardiology, 2013, 61, 971-980.	2.8	35
68	9-Month Clinical and Angiographic Outcomes of the COBRA Polyzene-F NanoCoated Coronary Stent System. JACC: Cardiovascular Interventions, 2017, 10, 160-167.	2.9	35
69	Very Late Pathological Responses to Cobaltâ€“Chromium Everolimusâ€Eluting, Stainless Steel Sirolimusâ€Eluting, and Cobaltâ€“Chromium Bare Metal Stents in Humans. Journal of the American Heart Association, 2017, 6, .	3.7	34
70	Isolated Right Ventricular Infarction. New England Journal of Medicine, 2003, 349, 1636-1636.	27.0	32
71	Embolic Myocardial Infarction as a Consequence of Atrial Fibrillation. Circulation, 2015, 132, 223-226.	1.6	31
72	Direct Targeting of the mTOR (Mammalian Target of Rapamycin) Kinase Improves Endothelial Permeability in Drug-Eluting Stentsâ€”Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2217-2224.	2.4	30

#	Article	IF	Citations
73	COVID-19â€“Associated cardiac pathology at the postmortem evaluation: a collaborative systematic review. Clinical Microbiology and Infection, 2022, 28, 1066-1075.	6.0	30
74	Hepcidin-ferroportin axis controls toll-like receptor 4 dependent macrophage inflammatory responses in human atherosclerotic plaques. Atherosclerosis, 2015, 241, 692-700.	0.8	29
75	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. Circulation, 2022, 145, 847-863.	1.6	28
76	Endothelial Barrier Protein Expression inÂBiodegradable Polymer Sirolimus-Eluting VersusÂDurable PolymerÂEverolimus-Eluting Metallic Stents. JACC: Cardiovascular Interventions, 2017, 10, 2375-2387.	2.9	27
77	ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) Expression and Localization of SARS-CoV-2 Infection in the Human Heart. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 542-544.	2.4	27
78	Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer-free stents. EuroIntervention, 2019, 14, 1685-1693.	3.2	27
79	Pharmacotherapy of coronary atherosclerosis. Expert Opinion on Pharmacotherapy, 2009, 10, 1587-1603.	1.8	26
80	Differential Healing After Sirolimus, Paclitaxel, and Bare Metal Stent Placement in Combination With Peroxisome Proliferator-Activator Receptor Î³ Agonists. Circulation Research, 2009, 105, 1003-1012.	4.5	24
81	Preclinical evaluation of a novel polyphosphazene surface modified stent. International Journal of Cardiology, 2016, 222, 217-225.	1.7	24
82	Thromboresistance and functional healing in the COBRA PzF stent versus competitor DES: implications for dual antiplatelet therapy. EuroIntervention, 2019, 15, e342-e353.	3.2	23
83	Biologic Drug Effect and Particulate Embolization of Drug-Eluting Stents versus Drug-Coated Balloons in Healthy Swine Femoropopliteal Arteries. Journal of Vascular and Interventional Radiology, 2018, 29, 1041-1049.e3.	0.5	22
84	Computational Fluid Dynamics Simulations of Hemodynamics in Plaque Erosion. Cardiovascular Engineering and Technology, 2013, 4, 464-473.	1.6	20
85	Pathological mechanisms of left main stent failure. International Journal of Cardiology, 2018, 263, 9-16.	1.7	20
86	Smooth Muscle Cellâ€“Specific PKM2 (Pyruvate Kinase Muscle 2) Promotes Smooth Muscle Cell Phenotypic Switching and Neointimal Hyperplasia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1724-1737.	2.4	19
87	Pathology of Chronic Total Occlusion in Bare-Metal Versus Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 367-378.	2.9	16
88	Revisiting the role of durable polymers in cardiovascular devices. Expert Review of Cardiovascular Therapy, 2017, 15, 835-846.	1.5	15
89	Safety of Zilver PTX Drug-Eluting Stent Implantation Following Drug-Coated Balloon Dilation in a Healthy Swine Model. Journal of Endovascular Therapy, 2018, 25, 118-126.	1.5	15
90	Coronary artery calcification. Current Opinion in Cardiology, 2018, 33, 645-652.	1.8	15

#	Article	IF	Citations
91	Vascular Response of a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) versus a Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) in Healthy Swine Femoropopliteal Arteries. Journal of Vascular and Interventional Radiology, 2021, 32, 792-801.e5.	0.5	15
92	Comparison of a Drugâ€Free Early Programmed Dismantling PDLLA Bioresorbable Scaffold and a Metallic Stent in a Porcine Coronary Artery Model at 3â€Year Followâ€Up. Journal of the American Heart Association, 2017, 6, .	3.7	14
93	Clinical implications of blood-material interaction and drug eluting stent polymers in review. Expert Review of Medical Devices, 2017, 14, 707-716.	2.8	14
94	Healthy Strut Coverage After Coronary Stent Implantation. Circulation: Cardiovascular Interventions, 2020, 13, e008869.	3.9	14
95	Histopathologic analysis of extracted thrombi from deep venous thrombosis and pulmonary embolism: Mechanisms and timing. Catheterization and Cardiovascular Interventions, 2021, 97, 1422-1429.	1.7	14
96	Sex Differences in Coronary Atherosclerosis. Current Atherosclerosis Reports, 2022, 24, 23-32.	4.8	14
97	Comprehensive Assessment of Human Accessory Renal Artery Periarterial Renal Sympathetic Nerve Distribution. JACC: Cardiovascular Interventions, 2021, 14, 304-315.	2.9	13
98	Metallic Coronary Stents. JACC: Cardiovascular Interventions, 2017, 10, 1175-1177.	2.9	12
99	What are the Pathological Concerns and Limitations of Current Drug-coated Balloon Technology?. Heart International, 2019, 13, 15.	1.4	12
100	Lessons Learned from Robotic-Assisted Coronary Artery Bypass Surgery: Risk Factors for Conversion to Median Sternotomy. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2012, 7, 323-327.	0.9	11
101	Everolimus-Eluting Stents Improve Vascular Response in a Diabetic Animal Model. Circulation: Cardiovascular Interventions, 2014, 7, 526-532.	3.9	11
102	The clinical challenge of disappearing stents. Lancet, The, 2016, 387, 510-512.	13.7	11
103	A new category stent with novel polyphosphazene surface modification. Future Cardiology, 2018, 14, 225-235.	1.2	11
104	Thromboresistance and endothelial healing in polymer-coated versus polymer-free drug-eluting stents: Implications for short-term dual anti-platelet therapy. International Journal of Cardiology, 2021, 327, 52-57.	1.7	11
105	What atherosclerosis findings can CT see in sudden coronary death: Plaque rupture versus plaque erosion. Journal of Cardiovascular Computed Tomography, 2020, 14, 214-218.	1.3	10
106	Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo. American Heart Journal, 2009, 157, 383.e1-383.e8.	2.7	9
107	Stenting of Spontaneous Coronary Artery Dissection From a Pathological Point of View. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	9
108	Pathologic intimal thickening: Are we any closer to understand early transitional plaques that lead to symptomatic disease?. Atherosclerosis, 2018, 274, 227-229.	0.8	9

#	Article	IF	Citations
109	Histopathologic and physiologic effect of overlapping vs single coronary stents: impact of stent evolution. Expert Review of Medical Devices, 2018, 15, 665-682.	2.8	9
110	Effects of Simulated COVID-19 Cytokine Storm on Stent Thrombogenicity. Cardiovascular Revascularization Medicine, 2022, 35, 129-138.	0.8	9
111	IN.PACT^{TM} Admiral^{TM} drug-coated balloons in peripheral artery disease: current perspectives . Medical Devices: Evidence and Research, 2019, Volume 12, 53-64.	0.8	8
112	Pathology and Multimodality Imaging ofÂAcute and Chronic Femoral Stenting inÂHumans. JACC: Cardiovascular Interventions, 2020, 13, 418-427.	2.9	8
113	Comparison of Endothelial Barrier Functional Recovery After Implantation of a Novel Biodegradable-Polymer Sirolimus-Eluting Stent in Comparison to Durable- and Biodegradable-Polymer Everolimus-Eluting Stents. Cardiovascular Revascularization Medicine, 2021, 24, 1-10.	0.8	8
114	Risk prediction of in-stent restenosis among patients with coronary drug-eluting stents: current clinical approaches and challenges. Expert Review of Cardiovascular Therapy, 2021, 19, 801-816.	1.5	8
115	APOL1 Genetic Variants Are Associated With Increased Risk of Coronary Atherosclerotic Plaque Rupture in the Black Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2201-2214.	2.4	8
116	Microâ€“Computed Tomography Demonstration of Multiple Plaque Ruptures in a Single Individual Presenting With Sudden Cardiac Death. Circulation: Cardiovascular Imaging, 2018, 11, e008331.	2.6	7
117	Co-Registration of Peripheral Atherosclerotic Plaques Assessed by Conventional CT Angiography, MicroCT and Histology in Patients with Chronic Limb Threatening Ischaemia. European Journal of Vascular and Endovascular Surgery, 2021, 61, 146-154.	1.5	7
118	Anticytomegalovirus CD4 + T Cells Are Associated With Subclinical Atherosclerosis in Persons With HIV. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1459-1473.	2.4	7
119	Comparison of acute thrombogenicity and albumin adsorption in three different durable polymer coronary drug-eluting stents. EuroIntervention, 2021, 17, 248-256.	3.2	7
120	Endothelial Recovery in Bare Metal Stents and Drug-Eluting Stents on a Single-Cell Level. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2277-2292.	2.4	7
121	COBRA PzFâ„¢ coronary stent in clinical and preclinical studies: setting the stage for new antithrombotic strategies?. Future Cardiology, 2022, 18, 207-217.	1.2	7
122	Characterization of Cerebral Embolic Capture Using the SENTINEL Device During Transcatheter Aortic Valve Implantation in Low to Intermediate-Risk Patients: The SENTINEL-LIR Study. Circulation: Cardiovascular Interventions, 2022, , CIRCINTERVENTIONS121011358.	3.9	7
123	Calcification in human vessels and valves: from pathological point of view. AIMS Molecular Science, 2020, 7, 183-210.	0.5	6
124	Bioresorbable vascular scaffolds. Coronary Artery Disease, 2017, 28, 533-538.	0.7	5
125	Histopathologic and physiologic effect of bifurcation stenting: current status and future prospects. Expert Review of Medical Devices, 2020, 17, 189-200.	2.8	5
126	Calcified nodule: A rare but important cause of acute coronary syndrome with worse clinical outcomes. Atherosclerosis, 2021, 318, 40-42.	0.8	5

#	Article	IF	Citations
127	Efficacy and safety of cerebral embolic protection systems during transcatheter aortic valve replacement: a review of current clinical findings. Expert Review of Cardiovascular Therapy, 2021, 19, 725-737.	1.5	5
128	Covering our tracks â€“ optical coherence tomography to assess vascular healing. EuroIntervention, 2018, 14, e1247-e1251.	3.2	5
129	Pathology of stent implantation in internal mammary artery. Cardiovascular Intervention and Therapeutics, 2019, 34, 1-8.	2.3	4
130	Response by Pellegrini et al to Letter Regarding Article, â€œMicrothrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Studyâ€• Circulation, 2021, 144, e158-e159.	1.6	4
131	Vulnerable Plaque in Patients with Acute Coronary Syndrome: Identification, Importance, and Management. US Cardiology Review, 0, 16, .	0.5	4
132	Eosinophils. Coronary Artery Disease, 2015, 26, 99-100.	0.7	3
133	Evaluation and Management of the Vulnerable Plaque. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	3
134	Cause of Stent Failure in Patients on Hemodialysis. Journal of the American Heart Association, 2020, 9, e018621.	3.7	3
135	Acute thrombogenicity of fluoropolymer coated stents versus competitive drug-eluting stents under single antiplatelet therapy. International Journal of Cardiology, 2021, 338, 42-49.	1.7	3
136	Response to Letter Regarding Article, â€œPathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelializationâ€• Circulation, 2007, 116, .	1.6	2
137	The Stress of Plaque Prognostication. JACC: Cardiovascular Imaging, 2018, 11, 472-475.	5.3	2
138	An uncommon but important cause of stent thrombosis: Kounis syndrome. Cardiovascular Revascularization Medicine, 2018, 19, 818-819.	0.8	2
139	Advances in mammalian target of rapamycin kinase inhibitors: application to devices used in the treatment of coronary artery disease. Future Medicinal Chemistry, 2020, 12, 1181-1195.	2.3	2
140	Nonatherosclerotic Vascular Disease in Women. Texas Heart Institute Journal, 2018, 45, 233-235.	0.3	2
141	Paradiseâ„¢ÂUltrasound Renal Denervation System for the treatment of hypertension. Future Cardiology, 2021, 17, 931-944.	1.2	1
142	Overcoming challenges in refining the current generation of coronary stents. Expert Review of Cardiovascular Therapy, 2021, 19, 1013-1028.	1.5	1
143	Pathology of drug-eluting stents: implications for coronary intervention. Indian Heart Journal, 2007, 59, B41-9.	0.5	1
144	Everolimus eluting stents: beyond targeting restenosis!. EuroIntervention, 2006, 2, 277-9.	3.2	1

#	Article	IF	Citations
145	Total erythrocyte membrane cholesterol: a marker of plaque instability?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 646-647.	3.3	0
146	Controversies Surrounding the Use of Drug-Eluting Stents. The American Heart Hospital Journal, 2007, 5, 141-145.	0.2	0
147	Herman Kalman Gold, MD. Circulation, 2008, 118, 1212-1213.	1.6	0
148	Illuminating Culprit Plaque Histology byÂOptical Coherence Tomography. JACC: Cardiovascular Interventions, 2015, 8, 1177-1179.	2.9	0
149	Biodegradable polymer drug-eluting stents: non-inferiority waiting for superiority?. Lancet, The, 2016, 388, 2567-2568.	13.7	0
150	Avances reveladores sobre la trombosis del stent. Revista Espanola De Cardiologia, 2017, 70, 1036-1038.	1.2	0
151	Catastrophic Consequence of Gauze During Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2017, 10, e141-e142.	2.9	0
152	Illuminating Insights Into Stent Thrombosis. Revista Espanola De Cardiologia (English Ed), 2017, 70, 1036-1038.	0.6	0
153	The Authors Reply:. JACC: Cardiovascular Imaging, 2018, 11, 518.	5.3	0
154	Types and pathology of vascular calcification. , 2019, , 1-25.		0
155	Imaging Human Platelet Adhesion and Albumin Retention to Coronary Stents in Real Time. Cardiovascular Revascularization Medicine, 2020, 21, 245-248.	0.8	0
156	Basic Pathology of Arterial and Valvular Calcification in Humans. Contemporary Cardiology, 2020, , 13-45.	0.1	0